NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology
Key Highlights
- ➤NeOnc will present NEO100 and NEO212 data at SNO on November 13, 2026
- ➤NEO100 poster details updated results from a Phase 1/2a study and compassionate use
- ➤NEO212 poster covers Phase 1 safety, pharmacokinetics, and early activity signals
- ➤NEO212 completed Phase 1 dose escalation and is advancing toward Phase 2
- ➤NEO100 and NEO212 remain investigational without established clinical safety or efficacy
Expert Statements
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc Technologies Holdings, Inc.
“We look forward to presenting data from both of our clinical programs at SNO”
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc Technologies Holdings, Inc.
“These presentations reflect the progress we are making in bringing new approaches to patients with brain cancer.”
CALABASAS, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that data from its intranasal NEO100 and oral NEO212 programs will be presented in two posters on Friday, November 13, at the 31st Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), held November 12 to 15, 2026, at the Pennsylvania Convention Center in Philadelphia.
“We look forward to presenting data from both of our clinical programs at SNO,” said Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc. “These presentations reflect the progress we are making in bringing new approaches to patients with brain cancer.”
Get started
Create a free account to read the full story.